Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review

1. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

GRAIL Inc. (GRAL:NASDAQ), a healthcare company focused on finding cancer earlier when treatment can be more effective, announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on Sept. 23 to evaluate the company's Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test, according to an August 7 release.

Galleri is intended to identify cancer-related methylation patterns common across numerous cancer types before symptoms develop, including cancers for which no recommended screening currently exists. When the test detects a cancer signal, it is designed to accurately identify its likely tissue of origin, helping physicians determine appropriate follow-up diagnostic testing. Galleri is intended to complement, rather than replace, guideline-recommended cancer screenings.

"Today, the status quo in cancer screening is simply unacceptable. Many cancers are detected too late, after symptoms appear and the disease is too advanced for effective or curative-intent treatments," said GRAIL Chief Executive Officer Dr. Josh Ofman. "In fact, 70-80% of cancer deaths occur due to cancers we are not screening for at all. GRAIL has pioneered a breakthrough technology, the Galleri test, designed to transform cancer screening by detecting more cancers before symptoms appear, including many of the deadly cancers that lack recommended screenings today."

The Galleri technology is unique in how it is designed to examine the methylome using proprietary technology and artificial intelligence, Ofman said.

"We have generated extensive data in multiple studies to evaluate the impact of adding Galleri to standard of care screening, with positive results showing evidence of increases in screen-detected cancers, a low false positive rate, and high signal origin prediction accuracy," he continued. "Adding Galleri to recommended screening could result in a more effective and efficient cancer screening program in the U.S."

Galleri is the only MCED test supported by large interventional and randomized, controlled studies in intended use populations, he said.

GRAIL filed the Galleri PMA application with the FDA on Jan. 29, after the agency designated the test as a Breakthrough Device in 2019. The submission centers on performance and safety data from 25,490 U.S. participants who consented to one year of follow-up in the PATHFINDER 2 study, along with results from more than 70,000 participants in the intervention group during the first year of the NHS-Galleri trial. The NHS-Galleri study is described as the largest and only randomized, controlled MCED trial conducted in an intended-use population. GRAIL also included an analysis comparing the Galleri version evaluated in PATHFINDER 2 and NHS-Galleri with the updated version submitted to the FDA for PMA review.

GRAIL is a healthcare company working to advance earlier cancer detection, with the goal of identifying the disease when it may still be curable.

The company said it seeks to reduce the worldwide impact of cancer by combining next-generation sequencing, large-scale clinical research, machine learning, software, and automation to detect and identify multiple deadly cancers at earlier stages. Its methylation-focused technology platform is designed to support cancer screening and precision oncology throughout the continuum of care. GRAIL is headquartered in Menlo Park, California, with additional operations in Washington, D.C., North Carolina, and the United Kingdom.

The Catalyst: FDA Advisory Committee Meeting

Per the FDA's notice in the Federal Register, the panel will "discuss, make recommendations, and vote" on the application, which proposes Galleri for the early detection of multiple cancers in adults aged 50 or older.

For GRAIL, the meeting is a pivotal regulatory checkpoint rather than a final decision. As the Federal Register notice states, the committee's role is "to provide advice and recommendations to FDA." Its vote is non-binding, and the agency retains the ultimate approval decision. However, as MedTech Dive's Susan Kelly reported on August 7, the FDA sides with its advisory committees roughly 80% of the time (TD Cowen's Dan Brennan pegged Galleri's approval odds at about 75%, according to the article). The stakes are elevated because, per a GRAIL news release, this is the first premarket approval application for an MCED test, and Kelly noted Galleri would become the first such test to win FDA approval if the agency signs off.

Co. Reports Improved Revenue for Galleri Test

On August 5, the company reported improved revenue and Galleri testing activity in the second quarter of 2026, although the company remained unprofitable.

GRAIL's second-quarter revenue increased 26% year over year to US$44.7 million, while Galleri test revenue rose 24% to US$42.6 million. Galleri test volume climbed 35% to more than 61,000 tests, and first-half Galleri revenue increased 30% to US$82.5 million as test volume advanced 42% to more than 117,000. The company posted a second-quarter net loss of US$110.2 million and a gross loss of US$12.6 million, while non-GAAP adjusted gross profit increased 34% to US$21.6 million and non-GAAP adjusted EBITDA showed a loss of US$90.3 million.

"GRAIL continues to execute across our clinical and commercial priorities," Ofman said at the time. "We presented detailed performance, safety, and clinical utility results from the NHS-Galleri and PATHFINDER 2 studies at the 2026 American Society of Clinical Oncology Annual Meeting, further establishing Galleri as the only MCED with extensive clinical validation from interventional studies in the screening population. We also expanded access through new and existing partnerships."

For the quarter ended June 30, 2026, GRAIL said total revenue increased US$9.1 million, or 26%, from the same period a year earlier, while its net loss narrowed by US$3.7 million, or 3%. Gross loss improved by US$5.2 million, or 29%, adjusted gross profit rose US$5.4 million, or 34%, and the adjusted EBITDA loss widened by US$11.9 million, or 15%.

Financial Expert: Product Will Likely Gain Approval

After the results, Chen Lin of What Is Chen Buying? What Is Chen Selling? noted the stock was "down hard on OK earnings."

Chen said he was buying back some shares that he trimmed at higher prices, but liked the fact that the advisory committee (ADCOM) meeting was coming soon.

"Usually, there is a run-up of stock heading into the ADCOM, then I can trim some to reduce my cost basis," Chen said. "Personally, I believe the product will likely get FDA approval as it is effective. You don't need to be 100% in cancer early detection, 50% is good enough, higher is better as they improve the technology."

Analysts' opinions were mixed and clustered close to the stock's current level of roughly US$75.60, according to TipRanks. The two most recent notes came on August 6: TD Cowen's Daniel Brennan reiterated a Buy at US$88 (about 16.37% upside), while Piper Sandler's David Westenberg reiterated a Hold at US$56, implying roughly 25.95% downside — the most bearish target on the board. On August 5, Canaccord Genuity's Kyle Mikson reiterated a Buy at US$80 (5.79% upside), and Guggenheim's Subbu Nambi reiterated a Buy at US$75, essentially at the current price (about 0.82% downside). Mizuho's Bradley Bowers held at a raised US$65 target on July 15, Goldman Sachs' Evie Koslosky initiated at Hold with a US$60 target on June 5, and Wolfe Research's Paige Chamberlain initiated at Hold with no target on June 1.

A Leading Cause of Death Worldwide

Cancer remains one of the leading causes of death worldwide, accounting for nearly 10 million deaths annually, noted DataM Intelligence in a release on October 7, 2025. 

"Traditional screening methods are cancer-specific, costly, and often invasive, leading to late-stage diagnoses that limit survival outcomes," the release said. "MCED tests — using liquid biopsies, genomic signatures, and AI-powered analysis — offer the ability to detect multiple cancers from a single blood draw, even before symptoms appear."

According to Grand View Research, the global multi-cancer early detection market size was estimated at US$1.3 billion in 2025 and is projected to grow from US$1.5 billion in 2026 to US$4.6 billion by 2033, growing at a CAGR of 17.2% from 2026 to 2033. The North American market held the largest share of 37.6% of the global market in 2025.

This market growth is attributed to an increase in the prevalence of multiple cancers, aided by the growing need to provide efficient methods to detect them at early stages to enable timely, appropriate treatment.

"For instance, according to the International Agency for Research on Cancer (IARC), ... over 35 million cases are predicted to occur by 2050," Grand View noted. "Moreover, early detection of cancer, particularly when it is localized and has not metastasized, significantly enhances the effectiveness and efficiency of treatment. This further enhances the need for advanced diagnostic solutions, which drives market growth. Emerging biological and informational technologies, including nanotechnology, big data analytics, artificial intelligence, machine learning, and genome sequencing, are revolutionizing diagnosis and therapy. These innovations drive breakthroughs in precision medicine, enabling early detection, personalized treatment plans, and improved patient outcomes."

Ownership and Share Structure¹

About 2% of the company is owned by Insiders and Management, about 3% by Strategic Corporate Investors, and 84% is held by Institutions. The rest is retail.

US$3.34 billion with 44.67 million shares outstanding. It trades in a 52-week range of US$29.95 and US$118.84.

Common Investor Questions

What is an advisory committee (ADCOM), and does its vote decide approval? An ADCOM is a panel of outside experts that the FDA convenes to review a product and vote on questions such as whether its benefits outweigh its risks. The vote is a recommendation — it is non-binding. The FDA usually follows its advisory committees but retains final decision authority on approval.

What is the Galleri test? Galleri is a blood test designed to identify cancer-related methylation patterns shared across numerous cancer types before symptoms appear, including cancers for which no recommended screening currently exists. When it detects a cancer signal, it is designed to predict the likely tissue of origin to guide follow-up testing. It is intended to complement, not replace, guideline-recommended screenings.

Why does this matter? CEO Dr. Josh Ofman says 70–80% of cancer deaths occur from cancers that are not screened for at all. GRAIL argues that adding Galleri to standard screening could produce a more effective and efficient U.S. cancer screening program, citing evidence of increased screen-detected cancers, a low false-positive rate, and high signal-origin prediction accuracy.

What do Wall Street analysts think? Opinion is mixed and clustered near the stock's level of roughly US$75.60. The most recent notes (August 6) were split: TD Cowen's Daniel Brennan reiterated Buy at US$88 (~16.37% upside), while Piper Sandler's David Westenberg reiterated Hold at US$56 (~25.95% downside), the most bearish target. On August 5, Canaccord Genuity's Kyle Mikson reiterated Buy at US$80, and Guggenheim's Subbu Nambi reiterated Buy at US$75. Mizuho's Bradley Bowers held at a raised US$65 target (July 15), while Goldman Sachs (US$60) and Wolfe Research (no target) each initiated at Hold in early June.